CONTINUE TO SITE
OR WAIT null SECS
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Impact of baseline OCT on response to risuteganib for treatment of intermediate AMD (ASRS 2020)
Justis P. Ehlers, MD, speaks on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)."
Justis P. Ehlers, MD, of the Cole Eye Institute at the Cleveland Clinic, speaks with Ophthalmology Times®' David Hutton on the key findings and take-aways from his presentation "Impact of baseline OCT characteristics on response to risuteganib for the treatment of intermediate age-related macular degeneration (AMD)" during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.
Related Content:
